Applicability of Serum Krebs von den lungen-6 as a Biological Exposure Index for Workers Exposed to Indium

인듐 노출 근로자를 위한 생물학적 노출지표로써 혈청 Krebs von den lungen-6의 활용가능성

  • Won, Yong Lim (Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency) ;
  • Yi, Gwang Yong (Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency) ;
  • Lee, Mi-Young (Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency) ;
  • Kim, Eun-A (Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency)
  • 원용림 (한국산업안전보건공단 산업안전보건연구원) ;
  • 이광용 (한국산업안전보건공단 산업안전보건연구원) ;
  • 이미영 (한국산업안전보건공단 산업안전보건연구원) ;
  • 김은아 (한국산업안전보건공단 산업안전보건연구원)
  • Published : 2013.06.30

Abstract

Objectives: Although several cases of lung diseases caused by indium have been reported in Japan, the United States and China, South Korea, which is estimated to have been the world's largest consumer of indium, has not yet established a criteria for the diagnosis of lung diseases caused by indium exposure. In this study, we tried to determine the applicability of the Krebs von den lungen-6, which has been widely recognized for its use with interstitial lung disease in Japan, as a biological exposure index for indium. Methods: Methods: The analysis of indium in serum was conducted by inductively coupled plasma mass spectrometry and the analysis of KL-6 in serum was carried out using enzyme-linked immunosorbent assay kit. Results: The indium levels in serum were distributed from below the detection limit to a peak of $125.78{\mu}g/L$, and the values of the KL-6 were distributed from 104.5 U/mL to 2162.2 U/mL. The serum indium and KL-6 showed good correlation ($R^2$=0.389,pfortrend=0.000) and smoking did not affect the KL-6. Conclusions: The usefulness of KL-6 as a specific biomarker for interstitial lung disease has been recognized. In addition, it is expected that effective prevention of health problems can be achieved by determining the lung-damage progress at an early stage according to individual susceptibility.

Keywords

References

  1. Abe T, Oda J, Takizawa Y, Suzuki E, Gejyo F. [Evaluation of serum fibrosis markers in asbestos-exposed workers]. Nihon Kokyuki Gakkai Zasshi. 2008;46(11):875-879
  2. Antje P, Joachim M-Q. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009;14(6):788-795 https://doi.org/10.1111/j.1440-1843.2009.01600.x
  3. Fumiko K, Hidefumi H, Hiromi H, Toshibumi K, Tadashi I et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004;98(11):1131-1137 https://doi.org/10.1016/j.rmed.2004.04.003
  4. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K et al. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997;156(1):109-115 https://doi.org/10.1164/ajrccm.156.1.9612043
  5. Ishikawa N, Kondo K, Oguri T, Kamitsuna M, Sakurai J et al. Usefulnesss of the modified lavage technique of Bingisser and KL-6 monitoring in a patient with pulmonary alveolar proteinosis. Intern Med 2002;41(5):381-385 https://doi.org/10.2169/internalmedicine.41.381
  6. Ishikawa N, Mazur W, Toljamo T, Vuopala K, Ronty M et al. Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med 2011;11:22 https://doi.org/10.1186/1471-2466-11-22
  7. Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K et al. Changes in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respir Res 2011;12:97 https://doi.org/10.1186/1465-9921-12-97
  8. Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers 2008;13(4):385-392 https://doi.org/10.1080/13547500801903651
  9. Kobayashi J, Kitamura S. KL-6: A serum marker for interstitial pneumonia. Chest 1995;108:311-315 https://doi.org/10.1378/chest.108.2.311
  10. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993;148(3):637-642 https://doi.org/10.1164/ajrccm/148.3.637
  11. Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994;8:81-83
  12. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pnuemonitis activity: Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73 https://doi.org/10.1378/chest.96.1.68
  13. Ministry of health, labour and welfare(MHLW) of Japan. The Technical Guideline for Preventing Health Impairment of Workers Engaged in the Indium Tin Oxide Handling Processes. 2010
  14. Nakajima M, Manabe T, Niki Y, Matsushima T. Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Thorax 1998;53(9):809-811. https://doi.org/10.1136/thx.53.9.809
  15. Nakano M, Omae K, Tanaka A, Hirata M, Michikawa T et al. Causal relationship between indium compound inhalation and effects on the lungs. J Occup Health. 2009;51(6):513-521 https://doi.org/10.1539/joh.L9077
  16. Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000;6(10):4069-4072
  17. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung disease. Am J Respir Crit Care Med 2002;165(3):378-381 https://doi.org/10.1164/ajrccm.165.3.2107134
  18. Okada F, Ando Y, Honda K, Tanoue S, Matsumoto S et al. Comparison of pulmonary CT findings and serum KL-6 levels in patients with cryptogenic organizing pneumonia. Br J Radiol 2009;82(975):212-218 https://doi.org/10.1259/bjr/72775434
  19. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006;260(5): 429-434 https://doi.org/10.1111/j.1365-2796.2006.01704.x
  20. Takahashi T, Munakata M, Ohtsuka Y, Satoh-Kamachi A, Sato R et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000;118(2):445-450 https://doi.org/10.1378/chest.118.2.445
  21. Takahashi T, Takamura K, Sakaue S, Ishii J, Yokouchi H et al. Elevated serum KL-6 concentrations in patients with diabetes mellitus. J Diabetes Complications 2002;16(5):352-358 https://doi.org/10.1016/S1056-8727(01)00220-3